Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 81 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo + olanzapine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Insulin Sensitivity Study in Healthy Subjects

NCT02922426
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ALKS 3831, Olanzapine, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metabolic Effects of Olanzapine in Healthy Males

NCT01496183
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants

NCT04535141
View directory record Official record
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Olanzapine 5 MG, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Hypochondriasis With CBT and/or SSRI

NCT00339079
View directory record Official record
Conditions
Hypochondriasis
Interventions
Fluoxetine, Cognitive Behavioral Therapy (CBT), Supportive Therapy, Placebo
Drug · Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prophylactic Olanzapine Versus Placebo for Prevention of Postoperative Delirium After Joint Replacement Surgery

NCT00699946
View directory record Official record
Conditions
Delirium
Interventions
olanzapine, placebo
Drug
Lead sponsor
The New England Baptist Hospital
Other
Eligibility
65 Years and older
Enrollment
495 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

NCT01234779
View directory record Official record
Conditions
Schizophrenia
Interventions
bitopertin [RO4917838], olanzapine, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
19
States / cities
Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 4 Interventional

Olanzapine in the Treatment of Anorexia Nervosa

NCT00592930
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
olanzapine, placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 23 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Oct 4, 2026, 6:42 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

NCT03781115
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine, Placebo Comparator
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

NCT03578081
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
565
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 4, 2026, 6:42 PM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (New Use) Weight Loss Study

NCT01272752
View directory record Official record
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Results available

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

NCT00981526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Telmisartan, Placebo, Clozapine, Olanzapine
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

Study of Amantadine for Weight Stabilization During Olanzapine Treatment

NCT00287352
View directory record Official record
Conditions
Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
Interventions
Olanzapine, Amantadine, Olanzapine and placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Ampakine Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

NCT00235352
View directory record Official record
Conditions
Schizophrenia
Interventions
CX516 (Ampakine)
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2009 · Synced Oct 4, 2026, 6:42 PM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

A Controlled Study of Olanzapine in Children With Autism

NCT00057408
View directory record Official record
Conditions
Autistic Disorder
Interventions
olanzapine (Zyprexa), Placebo
Drug
Lead sponsor
FDA Office of Orphan Products Development
Federal
Eligibility
3 Years to 12 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 4, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

NCT00734435
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions
zonisamide SR plus olanzapine, Placebo plus olanzapine
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
National City, California • Orange, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Placebo-Controlled, Cross-Over Trial of Aripiprazole

NCT00351936
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, placebo
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 4 Interventional Results available

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

NCT00690235
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Diabetes, Weight Gain
Interventions
Pramlintide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 4, 2026, 6:42 PM EDT
Recruiting Phase 2 Interventional

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

NCT05705492
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Modafinil on Olanzapine Weight Gain

NCT00636896
View directory record Official record
Conditions
Weight Gain
Interventions
Olanzapine plus modafinil, Olanzapine plus placebo
Drug
Lead sponsor
Neuropsychiatric Research Institute, Fargo, North Dakota
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2008 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Phase IIA Study in Patients With Schizophrenia

NCT00686998
View directory record Official record
Conditions
Schizophrenia
Interventions
AZD2624, Olanzapine, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 4, 2026, 6:42 PM EDT
Terminated Not applicable Interventional Results available

A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

NCT00203307
View directory record Official record
Conditions
Migraine
Interventions
Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Oct 4, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Olanzapine for Nausea After Surgery

NCT02755116
View directory record Official record
Conditions
Postoperative Nausea and Vomiting
Interventions
Olanzapine, Placebo
Drug
Lead sponsor
Jaime B Hyman
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 4, 2026, 6:42 PM EDT